MUTANT OF ANTI-CD40 ANTIBODY

摘要

PROBLEM TO BE SOLVED: To provide mutants of anti-CD40 antibody, which is expected as therapeutically efficacious, having been optimized as a drug by lowering the ADCC activity and CDC activity thereof.

SOLUTION: Provided are an agonistic anti-CD40 monoclonal antibody mutant in which at least the hinge region is a hinge region derived from a human IgG2 and which has a mutation and/or a substitution of one or more amino acids causing lowering in the ADCC activity and/or CDC activity in the constant region; and an antagonistic anti-CD40 antibody mutant which has at least one mutation and/or substitution causing lowering in the ADCC activity and/or CDC activity in the constant region.

COPYRIGHT: (C)2009,JPO&INPIT